Have known sensitivity to any component of paclitaxel
History of known radiation sensitivity syndrome
Subject has a known sensitivity to any of the components of the investigational product AGSP:
Known sensitivity to any of the products or components to be administered during dosing.
Pts with known sensitivity to any immunomodulatory drugs (IMiDs)
Known sensitivity to any of the products or components to be administered during dosing.
Known sensitivity or allergy to murine products or any component of RO, venetoclax, or rituximab.
Known sensitivity to immunoglobulins or any of the components to be administered during dosing.
Has had previous exposure to KD or known allergy/sensitivity to KD or any other ROCK- inhibitor.
Subject with known sensitivity to starch or starch-derived materials;
Known sensitivity to conductive hydrogels
Known sensitivity to any of the ingredients of the investigational product enfortumab vedotin (ASG-CE)
Patient has known sensitivity to any of the products to be administered during dosing
Known sensitivity to any of the study medication components
Has known sensitivity to any of the ingredients of:
Subject has known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D)
Patients with a known sensitivity to any of the products to be administered during treatment
Patients with preexisting known or suspected radiation sensitivity syndromes will be excluded
Known sensitivity to kanamycin and other aminoglycosides; patients with known hypersensitivity to kanamycin or any other aminoglycoside antibiotic will be excluded
Known sensitivity to any of the products to be administered during dosing
Patients with a known history of a severe allergy or sensitivity to wheat gluten
Known or suspected drug sensitivity to cytarabine or the investigational agent ficlatuzumab
Patients with known sensitivity to any immunomodulatory drugs (IMiDs)
Known sensitivity to gadolinium-DTPA.
History of sensitivity to, or history of conditions that are known to cause sensitivity to, radiation therapy
Hypersensitivity to HTI- or sensitivity to humanized monoclonal antibody products
Known sensitivity to any study medication
Known sensitivity to E. coli derived products.
Have a known sensitivity to any of the components of Andes-
Patients with known sensitivity to alcohol.
Known sensitivity to gadolinium-DTPA
 Subject has known sensitivity to immunoglobulins or any of the products or components to be administered during dosing.
Known sensitivity to any of the products to be administered during the study (e.g., calcium, or vitamin D)
Has known sensitivity to retinoic acid derivatives
Subject has known sensitivity to any of the components of the investigational product AGSE:
Sensitivity score =< 
Patient must not have known sensitivity to TRC or any formulation excipients
Known sensitivity to any of the ingredients of the investigational product AGSE
Known sensitivity to E. coli derived products or known sensitivity to any of the products to be administered during dosing
Has known sensitivity to capecitabine or metabolites
Known sensitivity or allergy to murine products.
Patients with a known sensitivity to any of the products to be administered during treatment and assessments.
Patients with known sensitivity to any of the products to be administered during the study (eg, mammalian derived products, calcium or vitamin D)
Patients with known sensitivity to retinoic acid derivatives
Known sensitivity to any of the components of the investigational product AGSE:
Prior sensitivity to plerixafor
Patients have known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D)
Known sensitivity or allergy to murine products.
Known hypersensitivity to any of the study drugs or sensitivity to murine products, or history of sensitivity to mannitol
Subject has known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D)
Known sensitivity to ferumoxytol
Sensitivity to conductive hydrogels
Known sensitivity to any of the products that will be administered during the study
Patient must not have known sensitivity to terameprocol or any formulation excipients
History of sensitivity to any component of SD-
Patients with known sensitivity or allergy to any components of AMP-
Known sensitivity to any of the ingredients of the investigational product AGS-CF
Known sensitivity or contraindication to any component of study treatment
Hyper sensitivity to fulvestrant treatment excipients
Has a known sensitivity to -FU
Has a known sensitivity to agents of similar biologic composition as ramucirumab DP or IMC-F, or other agents that specifically target VEGF
Subject has known sensitivity or allergy to heparin
Known sensitivity to bendamustine
Subject has known sensitivity to any of the products to be administered during dosing
Women with sensitivity to silver
Known sensitivity to omalizumab
Known sensitivity to conductive hydrogels.
Known sensitivity or allergy to fish or fish oil
Patients with known sensitivity or allergy to porcine materials
Sensitivity to silver
Sensitivity to amide-type local anesthetics
Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products, calcium or vitamin D)
Subjects with a known sensitivity to any of the Investigational Product components
Have sensitivity or allergy to fish and/or shellfish
Have sensitivity or allergy to soy and/or soybeans
Known sensitivity to any of the components of the Levulan Kerastick for topical solution
Known sensitivity or allergy to fish
Known sensitivity to any of the products to be administered during the study (e.g., calcium or vitamin D)
Known sensitivity or allergy to turmeric spices or curry
Subjects with known sensitivity to any device or products required for the RALP surgery; and
Demonstrate hyperinsulinemia with a quantitative insulin sensitivity check index (QUICK I) value =< .
Known sensitivity to fluorescent light
Known sensitivity to F FSPG or components of the preparation
Known sensitivity to fluorescent light
Known sensitivity to any of the study medication components or the chemotherapy regimen
A known history of contrast sensitivity
Sensitivity to filgrastim or to E. coli-derived recombinant protein products.
Known Stage IV ovarian cancer with brain metastases . Received an investigational agent in another clinical trial within  days prior to surgery . Known sensitivity to fluorescent light
Known or suspected sensitivity to diagnostic imaging contrast agents.
Known or suspected sensitivity to indocyanine green (ICG).
Known sensitivity to fluorescent light
Subject has known sensitivity to any of the products or components to be administered during dosing.
